Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study

  • 51-week clinical study confirms that  Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile1
  • Sandoz proposed biosimilar adalimumab is currently under review by the European Medicines Agency for the treatment of several immunological diseases
  • Sandoz expects that approval of biosimilar adalimumab would further improve access to treatment for people living with immunological diseases

 Holzkirchen, September 14, 2017 – Sandoz, a Novartis …

/by

Sandoz proposed biosimilar rituximab accepted for review by the FDA

  • Rituximab is indicated to treat blood cancers and immunological diseases such as rheumatoid arthritis1
  • Sandoz believes the comprehensive data package submitted to the FDA for review confirms that our biosimilar rituximab matches the reference medicine in terms of safety, efficacy and quality
  • The global leader in biosimilars, Sandoz has five biosimilars approved worldwide including biosimilar rituximab, which was approved in Europe* in June 20172

Holzkirchen, September 12, 2017 – …

/by